Table 6.
The associations between ESR2 rs3020449 and clinicopathological features of breast cancer
| Variables | Genotype | OR (95% CI) | |||||
|---|---|---|---|---|---|---|---|
| TT | CT | CC | CC vs.TT | CT vs.TT | CT/CC vs.TT | CC vs. TT/CT | |
| Tumor size (cm) | |||||||
| < 2 | 69 | 66 | 17 | ||||
| ≥ 2 | 107 | 164 | 36 | 1.37 (0.71–2.62) | 1.60 (1.06–2.43) | 1.55 (1.05–2.31) | 1.057 (0.57–1.95) |
| LN metastasis | |||||||
| No | 74 | 90 | 20 | ||||
| Yes | 102 | 140 | 33 | 1.20 (0.64–2.25) | 1.13 (0.76–1.68) | 1.14 (0.78–1.67) | 1.12 (0.62–2.02) |
| Histological grade | |||||||
| SBR 1–2 | 101 | 121 | 22 | ||||
| SBR 3 | 75 | 109 | 31 | 1.90 (1.02–3.54) | 1.21 (0.82–1.80) | 1.32 (0.90–1.93) | 1.70 (0.95–3.04) |
| Venous invasion | |||||||
| None-little | 114 | 146 | 32 | ||||
| Moderate-severe | 62 | 84 | 21 | 1.21 (0.64–2.27) | 1.06 (0.70–1.59) | 1.08 (0.73–1.61) | 1.17 (0.65–2.10) |
| ER | |||||||
| (−) | 85 | 101 | 16 | ||||
| (+) | 91 | 129 | 37 | 2.16 (1.12–4.17) | 1.19 (0.80–1.77) | 1.33 (0.91–1.94) | 1.96 (1.05–3.63) |
| PR | |||||||
| (−) | 83 | 102 | 23 | ||||
| (+) | 93 | 128 | 30 | 1.16 (0.63–2.16) | 1.12 (0.76–1.66) | 1.13 (0.77–1.65) | 1.09 (0.61–1.94) |
| Her-2 | |||||||
| (−) | 120 | 175 | 35 | ||||
| (+) | 56 | 55 | 18 | 1.10 (0.57–2.11) | 0.67 (0.43–1.04) | 0.74 (0.49–1.13) | 1.37 (0.74–2.51) |
| Ki–67 (%) | |||||||
| < 14 | 112 | 153 | 29 | ||||
| ≥ 14 | 64 | 77 | 24 | 1.45 (0.78–2.70) | 0.88 (0.58–1.33) | 0.97 (0.66–1.44) | 1.56 (0.87–2.77) |
The significant ORs and 95%CIs were presented in italic
LN axillary lymph node, ER estrogen receptor, PR progesterone receptor, Her-2 human epidermal growth factor receptor 2, SBR Scarff, Bloom and Richardson tumor grade, OR odds ratio; 95% CI confidence interval